Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Solid Tumors 1Pleural Effusion 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Multiple Myeloma 1Insulin-Like Growth Factor I, Resistance To 1Advanced Solid Tumors 1

Interventions

Carboplatin 171Paclitaxel 129Radiotherapy 119Cisplatin 109Docetaxel 93Gemcitabine 81Erlotinib Hydrochloride 80Pemetrexed 78Bevacizumab 56Etoposide 41pembrolizumab 36Gefitinib 32Vinorelbine 31Topotecan 30Surveys and Questionnaires 29Irinotecan 28Radiosurgery 21Nivolumab 20Drug Therapy 20Magnetic Resonance Spectroscopy 18Cetuximab 18durvalumab 17Early Intervention, Educational 17Blood Specimen Collection 17Surgical Procedures, Operative 16Cyclophosphamide 16Celecoxib 15Ipilimumab 14Immunohistochemistry 14Filgrastim 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lung Neoplasms × dalotuzumab × Clear all
NCT00869752 2023-08-04

MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Canadian Cancer Trials Group

Phase 1/2 Completed
12 enrolled
Thoracic

Lung Neoplasms

NCT00799240 2014-11-07

IMPACT

University of Kansas Medical Center

Phase 2 Completed
27 enrolled
Thoracic

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡